Evidence map›Paper›PMID 36370580›Full record

ArticleComputers in biology and medicine2022

Identification of potent compounds against SARs-CoV-2: An in-silico based drug searching against Mpro.

Muhammad Hassam, Muhammad Arslan Bashir, Sarah Shafi, Noor-Ul-Ain Zahra, Kanwal Khan, Khurshid Jalal, Hina Siddiqui, Reaz Uddin

Abstract read
In one paragraph

Article in Computers in biology and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Exploring the Therapeutic Potential ofMolecules (Basel, Switzerland) · 2024
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Muhammad HassamDr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan.
Muhammad Arslan BashirDepartment of Avionics Engineering, College of Aeronautical Engineering, National University of Science and Technology, Risalpur, Pakistan.
Sarah ShafiHEJ Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan.
Noor-Ul-Ain ZahraDr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan; Institute of Organismic and Molecular Evolution, Faculty of Biology, Johannes Gutenberg Universität, 55128, Mainz, Germany.
Kanwal KhanDr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan.
Khurshid JalalHEJ Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan.
Hina SiddiquiHEJ Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan.
Reaz UddinDr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan. Electronic address: mriazuddin@iccs.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The worldwide pandemic of coronavirus disease 2019 (COVID-19) along with the various newly discovered major SARS-CoV-2 variants, including B.1.1.7, B.1.351, and B.1.1.28, constitute the Variant of Concerns (VOC). It's difficult to keep these variants from spreading over the planet. As a result of these VOCs, the fifth wave has already begun in several countries. The rapid spread of VOCs is posing a serious threat to human civilization. There is currently no specific medicine available for the treatment of COVID-19. Here, we present the findings of methods that used a combination of structure-assisted drug design, virtual screening, and high-throughput screening to swiftly generate lead compounds against Mpro protein of SARs-CoV-2. Therapeutics, in addition to vaccinations, are an essential element of the healthcare response to COVID-19's persistent threat. In the current study, we designed the efficient compounds that may combat all emerging variants of SARs-CoV-2 by targeting the common Mpro protein. The present study was aimed to discover new compounds that may be proposed as new therapeutic agents to treat COVID-19 infection without any adverse effects. For this purpose, a computational-based virtual screening of 352 in-house synthesized compounds library was performed through molecular docking and Molecular Dynamics (MD) simulation approach. As a result, four novel potent compounds were successfully shortlisted by implementing certain pharmacological, physiological, and ADMET criteria i.e., compounds 3, 4, 21, and 22. Furthermore, MD simulations were performed to evaluate the stability and dynamic behavior of these compounds with Mpro complex for about 30 ns. Eventually, compound 22 was found to be highly potent against Mpro protein and was further evaluated by applying 100 ns simulations. Our findings showed that these shortlisted compounds may have potency to treat the COVID-19 infection for which further experimental validation is proposed as part of a follow-up investigation.

Indexed as

COVID-19 Drug TreatmentSARS-CoV-2HumansMolecular Docking SimulationMolecular Dynamics SimulationPandemicsProtease InhibitorsProtease InhibitorsCOVID-19Molecular docking and simulationMproSynthetic compoundsVirtual screening

Identifiers

PMID36370580
PMCPMC9635257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.